Inhaled corticosteroids as a cause of CAP

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 234-242

  Calverley, Peter M A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MULTICENTER STUDY (TOPIC);

EID: 84905718175     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10004613     Document Type: Article

References (46)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Sanz Herrero F, Blanquer Olivas J. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33: 220-231.
3. To M, To Y, Yamada H, et al. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern Med 2004; 43: 674-678.
4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
5. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
6. Spencer S, Calverley PM, Sherwood Burge P, et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128.
7. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J2003; 22: 912-919.
8. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008; 9: 73.
9. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
10. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropiumversussalmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
11. O'Reilly J, Jones MM, Parnham J, et al. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ2010; 340: c3134.
12. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
13. Calverley PM, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124: 1350-1356.
14. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J2009; 34: 641-647.
15. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J2012; 39: 38-45.
16. Rabe KF, Fabbri LM, Vogelmeier C, et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest 2013; 143: 711-719.
17. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
18. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505-512.
19. Mapel D, Schum M, Yood M, et al. Pneumonia among COPD patients using inhaled corticosteroids and longacting bronchodilators. Prim Care Respir J2010; 19: 109-117.
20. Singanayagam A, Chalmers JD, Akram AR, et al. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J2011; 38: 36-41.
21. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
22. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011; 184: 312-316.
23. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J2010; 36: 751-757.
24. Restrepo MI, Mortensen EM, Anzueto A. Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?Eur Respir J2011; 38: 1-3.
25. Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106: 1124-1133.
26. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
27. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD2009; 6: 320-329.
28. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respir Med 2013; 107: 550-559.
29. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterolversusvilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-23.
30. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
31. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting b2 agonist: observational matched cohort study (PATHOS). BMJ2013; 346: f3306.
32. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
33. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943.
34. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176: 454-459.
35. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
36. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-1080.
37. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome following rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1224-1231.
38. Patterson CM, Morrison RL, D'Souza A, et al. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniaein mice. Respir Res 2012; 13: 40.
39. Seemungal T, Stockley R, Calverley P, et al. Investigating new standards for prophylaxis in reduction of exacerbations-the INSPIRE study methodology. COPD2007; 4: 177-183.
40. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
41. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J2003; 22: 931-936.
42. Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J2010; 35: 1022-1030.
43. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183: 589-595.
44. McKeever T, Harrison TW, Hubbard R, et al. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case control study. Chest 2013; 144: 1788-1794.
45. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
46. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.